Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
10.17
-0.20 (-1.88%)
At close: Jul 18, 2025, 4:00 PM
10.50
+0.34 (3.30%)
After-hours: Jul 18, 2025, 7:49 PM EDT
Niagen Bioscience Employees
Niagen Bioscience had 104 employees as of December 31, 2024. The number of employees decreased by 2 or -1.89% compared to the previous year.
Employees
104
Change (1Y)
-2
Growth (1Y)
-1.89%
Revenue / Employee
$1,037,740
Profits / Employee
$135,625
Market Cap
802.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NAGE News
- 4 days ago - Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York - Business Wire
- 10 days ago - Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - Business Wire
- 24 days ago - Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends - Seeking Alpha
- 4 weeks ago - Niagen Bioscience to Participate at the Roth 15th Annual London Conference - Business Wire
- 5 weeks ago - Niagen Bioscience to Participate in the BIO 2025 International Convention - Business Wire
- 5 weeks ago - Niagen Bioscience: High Conviction, High Expectations - Seeking Alpha
- 5 weeks ago - Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder - Business Wire
- 6 weeks ago - Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference - Business Wire